Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-20, Stock:ABBV, The news for the past five days is as follows:
2018-02-12: NEWS1: Is AbbVie or Vertex Pharmaceuticals the Better Buy Now?.NEWS2: Is AbbVie or Vertex Pharmaceuticals the Better Buy Now?.NEWS3: 5 Solid Dividend Growth Stocks Amid Rising Rates.NEWS4: 5 Solid Dividend Growth Stocks Amid Rising Rates.NEWS5: Is AbbVie or Vertex Pharmaceuticals the Better Buy Now?.NEWS6: 5 Solid Dividend Growth Stocks Amid Rising Rates.NEWS7: 5 Solid Dividend Growth Stocks Amid Rising Rates.NEWS8: These 3 Drugs Are Critical to AbbVie's Success.NEWS9: These 3 Drugs Are Critical to AbbVie's Success.NEWS10: AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting.NEWS11: These 3 Drugs Are Critical to AbbVie&apos;s Success.NEWS12: Is AbbVie Inc’s (NYSE:ABBV) ROE Of 93.77% Sustainable?.
2018-02-13: NEWS1: Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning.NEWS2: Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning.NEWS3: Better Buy: Eli Lilly and Company vs. Johnson & Johnson.NEWS4: Better Buy: Eli Lilly and Company vs. Johnson & Johnson.NEWS5: Bristol-Myers Squibb’s Virology Products in 4Q17.NEWS6: Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning.
2018-02-14: NEWS1: AbbVie Appears Ready to Start a New Advance at Any Time.NEWS2: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS3: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS4: MTUM, BA, ABBV, C: ETF Inflow Alert.NEWS5: MTUM, BA, ABBV, C: ETF Inflow Alert.NEWS6: Inside Pfizer’s Inflammation and Immunology Portfolio Performances in 2017.NEWS7: Lilly&apos;s Taltz Positive in Phase III Label Expansion Study.NEWS8: 3 Top Stocks You Can Buy and Hold for the Next Decade.NEWS9: 3 Top Stocks You Can Buy and Hold for the Next Decade.NEWS10: Bristol-Myers Squibb’s Orencia and Other Brands in 4Q17.NEWS11: 3 Top Stocks You Can Buy and Hold for the Next Decade.NEWS12: 3 Dividend Stocks for In-the-Know Investors.NEWS13: 3 Dividend Stocks for In-the-Know Investors.NEWS14: 3 Dividend Stocks for In-the-Know Investors.NEWS15: Is Now a Good Time to Buy AbbVie?.NEWS16: Is Now a Good Time to Buy AbbVie?.NEWS17: Is Now a Good Time to Buy AbbVie?.
2018-02-15: NEWS1: AbbVie Stock Rises After Increasing Dividend By 35%.NEWS2: AbbVie to buy back $10 billion of shares, raises dividend.NEWS3: 5 Cheap Dividend Stocks With Growing Payouts.NEWS4: 6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One's a Marijuana Stock).NEWS5: 6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One's a Marijuana Stock).NEWS6: AbbVie to buy back $10 billion of shares, raises dividend.NEWS7: AbbVie to buy back $10 billion of shares, raises dividend.NEWS8: AbbVie stock rises after dividend boosted 35%, new $10 billion buyback program.NEWS9: AbbVie Increases Dividend and Announces New Stock Repurchase Program.NEWS10: How Analysts View Bristol-Myers Squibb after Its 4Q17 Earnings.NEWS11: [$$] AbbVie shares the wealth with dividend boost, $10bn in buybacks.
2018-02-16: NEWS1: Health Care Sector Update for 02/16/2018: ABBV,APRI,UTHR,PCRX.NEWS2: Health Care Sector Update for 02/16/2018: ABBV,APRI,UTHR,PCRX.NEWS3: AbbVie Inc. -- Moody's says AbbVie's shareholder payouts are credit negative.NEWS4: How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients.NEWS5: AbbVie Inc (ABBV) Files 10-K for the Fiscal Year Ended on December 31, 2017.NEWS6: Novartis’s Cosentyx May Emerge as a Leading Psoriasis Drug.NEWS7: Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017.NEWS8: Top-Rated Stocks: Zoetis Sees Composite Rating Climb To 97.NEWS9: Top-Rated Stocks: Zoetis Sees Composite Rating Climb To 97.NEWS10: Stocks To Watch: Bristol-Myers Squibb Sees RS Rating Jump To 83.NEWS11: Stocks To Watch: Bristol-Myers Squibb Sees RS Rating Jump To 83.NEWS12: AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks.NEWS13: Coca-Cola earnings show the beverage business—not bottling—is booming.NEWS14: AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan.NEWS15: AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan.NEWS16: Merck’s Immunology and Cardiovascular Products in 4Q17.NEWS17: AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan.NEWS18: Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?.NEWS19: Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?.NEWS20: Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?.NEWS21: 5 Cheap Dividend Stocks with Growing Payouts.NEWS22: 5 Cheap Dividend Stocks with Growing Payouts.NEWS23: AbbVie Stock Rises After Increasing Dividend By 35%.NEWS24: AbbVie Stock Rises After Increasing Dividend By 35%.

Answer: Decrease